TransCode Theraupetics completed the acquisition of Polynoma from CK Life Sciences.

TransCode Theraupetics, a Boston-based biotechnology company focused on oncology, completed the acquisition of Polynoma, an immuno-oncology focused biopharmaceutical company, from CK Life Sciences, a company which is engaged in healthcare research and development. Financial terms were not disclosed. "This acquisition allows us to create a unique and broader pipeline with Phase 3 ready seviprotimut-L, and potentially realize synergies between both technologies, for the ultimate benefit of patients suffering from cancer and metastases. Between the two programs, we see a unique potential to augment seviprotimut-L's focus with our microRNA lead program, TTX-MC138, by addressing the micrometastases in stage IIB and IIC melanoma patients," Dr. Philippe Calais, TransCode Therapeutics CEO.